Search - tctmd.com

Displaying 461 - 480 of 765

Sort: Relevancy | Date

News Conference News ESC 2016

When Unblinded to Statin Therapy, Patients’ Muscle-Related Adverse Events Shoot Up: ASCOT Analysis

Michael O'Riordan

August 31, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Daily News

更高效、更廉价：成本效益分析称 PCSK9 价格需降低三分之二

Yael L. Maxwell

August 29, 2016

News Daily News

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Yael L. Maxwell

August 29, 2016

News Daily News

Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9

Yael L. Maxwell

August 29, 2016

News Conference News ESC 2016

Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC

Todd Neale

August 28, 2016

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

News Daily News

Noninvasive Testing Can Safely Spare a Large Proportion of Elderly Patients From Statin Therapy

Michael O'Riordan

August 23, 2016

News Daily News

Improved Adherence to Medical Therapy Reduces CVD Events in Secondary Prevention Patients

Michael O'Riordan

August 16, 2016

News Daily News

药物治疗的使用不足与高龄患者不良事件增多相关

Michael O'Riordan

July 21, 2016

News Daily News

Underuse of Medical Therapy Linked With Increased Adverse Events in Very Elderly

Michael O'Riordan

July 21, 2016

News Daily News

La Infrautilización del Tratamiento Médico se asocia a Más Episodios Adversos en Pacientes Muy Ancianos

Michael O'Riordan

July 21, 2016

News Daily News

Judge Dismisses AstraZeneca’s Bid to Block Generic Crestor

Shelley Wood

July 20, 2016

News Daily News

欧盟与美国血脂指南辩论：专家称重要的是差距

Shelley Wood

July 19, 2016

News Daily News

The EU Versus US Lipid Guideline Debate: It’s the Gap That Matters, Experts Say

Shelley Wood

July 19, 2016

Presentation

Antiplatelet Therapy and Outcomes in Patients Undergoing Surgery After Stenting

Presenter: Roberta Rossini

July 18, 2016

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

Statins Lower but Don’t Erase the Excess Risk of Coronary Disease and Death in Familial Hypercholesterolemia

Todd Neale

July 12, 2016

News Daily News

Timing and Type of Events Post-PCI Have Implications for Prognosis—and Honest Discussions With Patients

Yael L. Maxwell

July 05, 2016

Advertisement

When Unblinded to Statin Therapy, Patients’ Muscle-Related Adverse Events Shoot Up: ASCOT Analysis

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

更高效、更廉价：成本效益分析称 PCSK9 价格需降低三分之二

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9

Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Noninvasive Testing Can Safely Spare a Large Proportion of Elderly Patients From Statin Therapy

Improved Adherence to Medical Therapy Reduces CVD Events in Secondary Prevention Patients

药物治疗的使用不足与高龄患者不良事件增多相关

Underuse of Medical Therapy Linked With Increased Adverse Events in Very Elderly

La Infrautilización del Tratamiento Médico se asocia a Más Episodios Adversos en Pacientes Muy Ancianos

Judge Dismisses AstraZeneca’s Bid to Block Generic Crestor

欧盟与美国血脂指南辩论：专家称重要的是差距

The EU Versus US Lipid Guideline Debate: It’s the Gap That Matters, Experts Say

Antiplatelet Therapy and Outcomes in Patients Undergoing Surgery After Stenting

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Statins Lower but Don’t Erase the Excess Risk of Coronary Disease and Death in Familial Hypercholesterolemia

Timing and Type of Events Post-PCI Have Implications for Prognosis—and Honest Discussions With Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content